Efficacy and safety of lanthanum carbonate in german patients on dialysis

Clinical Nephrology

Volumn 78, Issue 5, 2012, Pages 382-390

  Dellanna, Frank ^a   Reichel, Helmut ^b   Seibt, Frank ^c  

^a Dialysis Center   (Germany)

^b Nephrological Center   (Germany)

^c Dialysis Center Am Treptower Park   (Germany)

Author keywords

Hyperphosphatemia; Lanthanum carbonate; Post marketing surveillance; Tablet burden

Indexed keywords

ALFACALCIDOL; ALUMINUM; ALUMINUM HYDROXYCHLORIDE; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; LANTHANUM CARBONATE; PHOSPHATE; SEVELAMER;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGITATION; ARTICLE; CALCIUM BLOOD LEVEL; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GERMANY; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPERTENSIVE CRISIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; NAUSEA; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; POSTMARKETING SURVEILLANCE; PRURITUS; SEPSIS; SIDE EFFECT; SUDDEN DEATH; TREATMENT DURATION; VOMITING;

ADULT; AGED; CALCIUM; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RENAL DIALYSIS; TABLETS;

EID: 84871535125     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107330     Document Type: Article

References (24)

1. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010; 78: 975-980.
2. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, Sarro F, Valdivielso JM, Fernandez E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial, Transplant. 2007; 22: 1171-1176.
3. D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl. 2003; 63 (s85): S73-S78.
4. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005; 68: 1815-1824.
5. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger NK, Wilson PW, Wright JT Jr. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998; 32: 853-906.
6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15: 2208-2218.
7. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138.
8. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004; 15: 770-779.
9. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32 (Suppl 3): S112-S119.
10. Chiu YW, Teitelbaum I, Misra M, de Leon EM, Adzize T, Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009; 4: 1089-1096.
11. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol. 2008; 9: 2.
12. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005; 67: 1179-1187.
13. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskühler A. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract. 2006; 102: c61-c71.
14. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA; SPD405-309 Lanthanum Study Group. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract. 2008; 110: c15-c23.
15. Joy MS, Finn WF. LAM-302 Study Group. Randomized, double-blind, placebo-controlled, dosetitration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003; 42: 96-107.
16. Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005; 100: c8-c19.
17. World Health Organization. Adherence to longterm therapies, evidence for action. Geneva: World Health Organization; 2003.
18. Cleary DJ, Matzke GR, Alexander AC, Joy MS. Medication knowledge and compliance among patients receiving long-term dialysis. Am J Health Syst Pharm. 1995; 52: 1895-1900.
19. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001; 23: 1296-1310.
20. Freemont AJ, Hoyland JA, Denton J, Lanthanum Carbonate SPD405-303 Study Group. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol. 2005; 64: 428-437.
21. Malluche HH, Siami GA, Swanepoel C, Wang GH, Mawad H, Confer S, Smith M, Pratt RD, Monier-Faugere MC. SPD405-307 Lanthanum Carbonate Study Group. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol. 2008; 70: 284-295.
22. Altmann P, Barnett ME, Finn WF. SPD405-307 Lanthanum Carbonate Study Group. Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int. 2007; 71: 252-259.
23. Finn WF SPD 405-307 Lanthanum Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol. 2006; 65: 191-202.
24. Hutchison AJ, Barnett ME, Krause R, J, Siami GA. Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol. 2009; 71: 286-295.